tbuckley/cabot-search huggingface dataset:
Artificial Intelligence and Machine Learning in Dermatological Research and Healthcare: British Society for Investigative Dermatology Skin Club Report - Southampton April 2024
Authors: Chester Lai, Nicholas R Fuggle, Rubeta N Matin, Reiko J Tanaka, Christopher R S Banerji, Neil Rajan
Journal: British Journal of Dermatology (2024)

The British Society for Investigative Dermatology champions the development of clinical trainees and early-career researchers, and convenes the UK skin research community at its annual meeting. It is the privilege of the meeting organizer (Dr Chester Lai) to invite key opinion leaders to speak during the ‘Skin Club’ section of the meeting, a forum for dialogue with this young audience on disruptive advances that stand to shape skin science. This year in Southampton, the topic ‘Artificial Intelligence and Machine Learning in Dermatological Research and Healthcare’ was selected.
Joint exposure to multiple air pollutants, genetic risk, and incident psoriasis: a large-scale prospective cohort study
Authors: Yan Xiong, Yuting Xia, Xinyue Zhang, Biling Jiang, Zeling Zhang, Chunhui Xie, Xiaoping Miao, Jiajia Lan, Juan Tao
Journal: British Journal of Dermatology (2024)

Abstract Background Air pollution and genetic risk have been found to contribute to both onset and development of psoriasis. However, the extent to which genetic susceptibility modifies the effects of air pollutants on the risk of incident psoriasis remains unknown. Objectives Our study aimed to assess the association between joint exposure to multiple air pollutants and the risk of psoriasis and the modification by the genetic susceptibility. Methods This prospective study included 451,064 participants with complete air pollution data and free of psoriasis at baseline from the UK Biobank. All participants were enrolled from 2006 to 2010 and followed up to 2022. The air pollution score (APS) was calculated to assess the joint exposure to multiple air pollutants, including particulate matter (PM) with diameters ≤ 2.5 μm (PM2.5), between 2.5 and 10 μm (PM2.5−10), and ≤ 10 μm (PM10), as well as nitrogen dioxide (NO2) and nitrogen oxides (NOx). To evaluate the genetic risk, the polygenic risk score (PRS) for psoriasis was constructed. The Cox proportional hazard models were used to assess the association of air pollution and genetic susceptibility with the risk of psoriasis. Stratified analyses were conducted based on the individual characteristics. Results During a median follow-up of 13.79 years, 4414 psoriasis events were recorded. The hazard ratios (HRs) [95% confidence intervals (CIs)] for psoriasis were 1.036 (0.936-1.147), 1.091 (0.987-1.206), 1.159 (1.048-1.283), and 1.163 (1.052-1.286) in higher quintile groups compared with the lowest quintile of APS (P trend &amp;lt;0.05). When considering genetic susceptibility, participants with high PRS and high APS had the greatest risk of incident psoriasis [HR (95% CI): 1.962 (1.630-2.362)] than those with low PRS and low APS. The HRs (95% CIs) for PM2.5-10, NOx, PM2.5 absorbance, PM2.5, NO2, and PM10 in the group with high exposure level and genetic risk were 1.831 (1.537-2.181), 1.722 (1.431-2.073), 1.698 (1.416-2.037), 1.619 (1.353-1.938), 1.504 (1.252-1.806), and 1.425 (1.192-1.704), respectively. Conclusions Long-term exposure to various air pollutants is positively associated with an increased risk of incident psoriasis, particularly in individuals with high genetic risk. More comprehensive measures are needed to reduce the air pollution levels for better prevention of psoriasis.
The management of atopic dermatitis in women of childbearing age: confused terminology, lack of evidence and resulting clinical inertia
Authors: Ruchika Kumari, Christian J Apfelbacher, Catherine Nelson-Piercy, Carsten Flohr
Journal: British Journal of Dermatology (2024)

Confusion in definitions, conflicting opinions and limited evidence leave women of childbearing age with eczema, and treating clinicians, vulnerable to restrictive therapeutic practices.
Normalization of short-chain fatty acid concentration by bacterial count of stool samples improves discrimination between eubiotic and dysbiotic gut microbiota caused by <i>Clostridioides difficile</i> infection-
Authors: Anna Sayol-Altarriba, Andrea Aira, Anna Villasante, Rosa Albarracín, Joana Faneca, Gregori Casals, José Luis Villanueva-Cañas, Climent Casals-Pascual
Journal: Gut Microbes (2024)

Short-chain fatty acids (SCFAs) represent a cornerstone of gut health, serving as critical mediators of immune modulation and overall host homeostasis. Patients with dysbiosis caused by
Avatrombopag in immune thrombocytopenia: A real‐world study of the Spanish ITP Group (GEPTI)
Authors: Cristina Pascual‐Izquierdo, Blanca Sánchez‐González, Mariana‐Isabel Canaro‐Hirnyk, Gloria García‐Donas, María Menor‐Gómez, Juan‐José Gil‐Fernández, Silvia Monsalvo‐Saornil, Almudena de‐Laiglesia, María‐Teresa Álvarez‐Román, Isidro Jarque‐Ramos, María‐José Llácer, Begoña Pedrote‐Amador, Denis Zafra‐Torres, Isabel Caparrós‐Miranda, Ariana Ortúzar‐Pasalodos, Nuria Revilla‐Calvo, José‐María Bastida, Esther Chica‐Gullón, Montserrat Alvarellos, Reyes Jiménez‐Bárcenas, Silvia Bernat, Daniel Martínez‐Carballeira, Sunil Lakhwani, Elsa López‐Ansoar, María‐Esperanza Moreno‐Beltrán, Álvaro Lorenzo‐Vizcaya, María‐Aránzazu Aguirre, Maialen Lasa‐Eguialde, Marta Canet, Isabel‐Teresa González‐Gascón‐y‐Marín, Gonzalo Caballero‐Navarro, Amalia Cuesta, Marta Díaz‐López, Teresa Arquero, Marta Moreno‐Carbonell, María‐Eva Mingot‐Castellano
Journal: American Journal of Hematology (2024)

Abstract Avatrombopag is the newest thrombopoietin receptor agonist (TPO‐RA) approved to treat immune thrombocytopenia (ITP). Real‐world evidence regarding effectiveness/safety is limited. The Spanish ITP Group (GEPTI) performed a retrospective study with patients starting avatrombopag for the first time. A total of 268 ITP patients were recruited. The median (interquartile range [IQR]) follow‐up time was 47.5 (30.4–58.9) weeks. Among the 193 patients with baseline platelet counts &lt;50 × 10 9 /L, 174 (90.1%) of them achieved response (PC ≥50 × 10 9 /L), and 113 (87.6%) of the 129 who persisted on avatrombopag at last visit had platelet levels above such threshold. Results were similar when only those patients switching to avatrombopag due to previous treatment failure were considered ( n = 104). Patients reached response in 13 (7–21) days. Among patients with baseline levels ≥50 × 10 9 /L, 73/75 (97.3%) reported response, which was maintained by 53 (94.6%) of the 56 who continued on avatrombopag at the end of the study. Loss‐of‐response was always &lt;10%. ITP duration did not influence response. Approximately 79% (34/43) of heavily pretreated (≥4 lines) patients with baseline platelet counts &lt;50 × 10 9 /L switching after previous failure achieved PC ≥50 × 10 9 /L. Previous use of eltrombopag and/or romiplostim did not influence response, regardless of whether previous TPO‐RA(s) succeeded or failed. Avatrombopag allowed dose‐reduction/suspension of corticosteroids in 40/50 (80.0%) patients with baseline platelet counts &lt;50 × 10 9 /L. Overall, 40/268 (14.9%) thrombocytosis and 12/268 (4.5%) thromboembolic events were reported. Our real‐world cohort supports the use of avatrombopag to manage ITP, regardless of disease severity and treatment history.
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis
Authors: Lianxuan Liu, Mi Shao, Yue Huang, Pengxu Qian, He Huang
Journal: Journal of Hematology & Oncology (2024)

Due to spatial and genomic independence, mitochondria possess a translational mechanism distinct from that of cytoplasmic translation. Several regulators participate in the modulation of mitochondrial translation. Mitochondrial translation is coordinated with cytoplasmic translation through stress responses. Importantly, the inhibition of mitochondrial translation leads to the inhibition of cytoplasmic translation and metabolic disruption. Therefore, defects in mitochondrial translation are closely related to the functions of hematopoietic cells and various immune cells. Finally, the inhibition of mitochondrial translation is a potential therapeutic target for treating multiple hematologic malignancies. Collectively, more in-depth insights into mitochondrial translation not only facilitate our understanding of its functions in hematopoiesis, but also provide a basis for the discovery of new treatments for hematological malignancies and the modulation of immune cell function.
SINE RNA of the imprinted miRNA clusters mediates constitutive type III interferon expression and antiviral protection in hemochorial placentas
Authors: Ishani Wickramage, Jeffrey VanWye, Klaas Max, John H. Lockhart, Ismet Hortu, Ezinne F. Mong, John Canfield, Hiran M. Lamabadu Warnakulasuriya Patabendige, Ozlem Guzeloglu-Kayisli, Kimiko Inoue, Atsuo Ogura, Charles J. Lockwood, Kemal M. Akat, Thomas Tuschl, Umit A. Kayisli, Hana Totary-Jain
Journal: Cell Host & Microbe (2024)
Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events
Authors: Limor Rubin, Aviv Talmon, Yaarit Ribak, David Lavie, Hovav Nechushtan, Nadia Caplan, Michal Lotem, Oded Shamriz, Irit Adini, Yuval Tal
Journal: Journal for ImmunoTherapy of Cancer (2024)

Given the broad implementation of immune checkpoint inhibitors (ICI) for cancer therapy, we encounter a variety of immune-related adverse events (irAE) including immune-related blood eosinophilia. Eosinophilia demonstrated a potential positive predictive marker for a beneficial clinical response to ICI. However, there are reports of eosinophil-induced adverse events (Eo-irAE) with organ dysfunction requiring initiation of oral glucocorticoid therapy and discontinuation of ICI.We aim to assess the efficacy and safety of interleukin (IL) 5-axis inhibition in Eo-irAE secondary to ICI therapy.We present three cases of Eo-irAE referred to our allergy and clinical immunology unit at Hadassah Hebrew University Medical Center following therapy with pembrolizumab and nivolumab, monoclonal antibodies that target the programmed cell death 1 (PD-1) receptor, for two cases of melanoma and one metastatic non-small cell lung carcinoma. Following informed consent and committee approval, two patients were treated with 1-3 doses of mepolizumab, 100 mg, monoclonal IgG1 kappa anti-IL-5 antibody, and one patient received up-to-date 9 doses of benralizumab, 30 mg, monoclonal IgG1 kappa antibody directed against the alpha chain of the interleukin-5 receptor, both administered subcutaneously. Patients were carefully followed and treatment response was assessed by physical examinations and laboratory tests.Hypereosinophilia at the level of 2300-8000 K/UL was observed 8-12 months following therapy accompanied by symptoms of dyspnea, arthralgia, myalgia, fasciitis, 'morphea'-like lesions, fatigue, abdominal discomfort, pruritus, and chest pain. ICI discontinuation did not improve symptoms, two patients were resistant to glucocorticoids and therefore biological treatment was initiated to inhibit the IL5 axis. Patients demonstrated rapid clinical response and a decrease in peripheral blood eosinophil levels with long-term symptoms remission. There were no signals of negative impacts, such as tumor progression following IL5 axis inhibition.Eosinophilia secondary to ICI therapy can lead to organ dysfunction. Discontinuation of ICI might not be effective and symptoms may be refractory to steroid therapy hence targeted inhibition of the IL5 axis should be considered.
Cancer-associated foam cells hamper protective T cell immunity and favor tumor progression in human colon carcinogenesis
Authors: Elena Daveri, Barbara Vergani, Luca Lalli, Giulio Ferrero, Elena Casiraghi, Agata Cova, Marta Zorza, Veronica Huber, Manuela Gariboldi, Patrizia Pasanisi, Simonetta Guarrera, Daniele Morelli, Flavio Arienti, Marco Vitellaro, Paola A Corsetto, Angela M Rizzo, Martina Stroscia, Paola Frati, Vincenzo Lagano, Laura Cattaneo, Giovanna Sabella, Biagio E Leone, Massimo Milione, Luca Sorrentino, Licia Rivoltini
Journal: Journal for ImmunoTherapy of Cancer (2024)

Colorectal cancer (CRC) remains a significant healthcare burden worldwide, characterized by a complex interplay between obesity and chronic inflammation. While the relationship between CRC, obesity and altered lipid metabolism is not fully understood, there are evidences suggesting a link between them. In this study, we hypothesized that dysregulated lipid metabolism contributes to local accumulation of foam cells (FC) in CRC, which in turn disrupts antitumor immunosurveillance.
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors
Authors: Qin Ding, Youliang Weng, Ying Li, Wanzun Lin, Xiaosan Lin, Tingting Lin, Hanxuan Yang, Wenqian Xu, Jianmin Wang, Hongmei Ying, Sufang Qiu
Journal: Journal for ImmunoTherapy of Cancer (2024)

The landscape of the tumor microenvironment (TME) is intricately linked to the development of head and neck squamous cell carcinoma (HNSCC) and significantly influences immunotherapy efficacy. Recent research has underscored the pivotal role of PNCK in cancer progression, yet its relationship with immunotherapy remains elusive.
In situ photocrosslinkable hydrogel treats radiation-induced skin injury by ROS elimination and inflammation regulation
Authors: Jintao Shen, Wencheng Jiao, Junzhe Yang, Bo Zhuang, Shumin Du, Yanping Wu, Guiyu Huang, Yizhi Zhang, Yaxin Wang, Caixia Xu, Lina Du, Yiguang Jin
Journal: Biomaterials (2024)
Duration of antimicrobial treatment for uncomplicated streptococcal bacteraemia: another example of shorter is better
Authors: Nicolas Fourré, Virgile Zimmermann, Laurence Senn, Marion Aruanno, Benoit Guery, Matthaios Papadimitriou-Olivgeris
Journal: Journal of Infection (2024)

Duration of treatment for uncomplicated streptococcal bacteraemia is unknown. The study aims to assess clinical outcomes of patients with uncomplicated streptococcal bacteraemia receiving a short course (5-10 days) of antimicrobial treatment compared to those receiving the traditional, longer duration (11-18 days).
Sex and gender in inflammatory bowel disease outcomes and research
Authors: Vibeke Andersen, Jessica Pingel, Heidi Lynge Søfelt, Zainab Hikmat, Mads Johansson, Vera Slyk Pedersen, Benthe Bertelsen, Anne Carlsson, Marie Lindh, Edda Svavarsdóttir, Dirk Repsilber, Maiken Thyregod Joergensen, Robin Christensen, Anja Fejrskov, Johannes David Füchtbauer, Jens Kjeldsen, Michael Dam Jensen, Claus Aalykke, Martin Rejler, Marte Lie Høivik, Loa Davidsdottir, Marie Carlson, Jonas Halfvarson, Heidi Holt Zachariassen, Liv Baisner Petersen, Eva Sophia Myers
Journal: The Lancet. Gastroenterology & hepatology (2024)
Nano-based perivascular intervention sustains a nine-month long-term suppression of intimal hyperplasia in vein grafts
Authors: Takuro Shirasu, Go Urabe, Nisakorn Yodsanit, Yitao Huang, Ruosen Xie, Matthew S. Stratton, Matthew Joseph, Zhanpeng Zhang, Yuyuan Wang, Jing Li, Runze Tang, Lynn M. Marcho, Li Yin, Eric W. Kent, Kaijie Zhang, Ki Ho Park, Bowen Wang, K. Craig Kent, Shaoqin Gong, Lian-Wang Guo
Journal: Bioactive Materials (2024)
“Grasping on a spider web of hope”: Psychological challenges and impact of waiting to access UK gender dysphoria Clinics on young adults
Authors: Luke Squires, Anna Laws, H. Eli Joubert, Beth Greenhill
Journal: International Journal of Transgender Health (2024)

Background Young transgender adults report higher levels of mental health difficulties compared to the general population. These difficulties reportedly improve following gender-affirming care and transition. However, gender-dysphoric people wait up to 5+ years in the UK to access gender-affirming treatment.
<i>Entamoeba muris</i> mitigates metabolic consequences of high-fat diet in mice
Authors: Maryline Roy, Anne Dumay, Sandrine Adiba, Sylvana Rozes, Seiki Kobayashi, Valérie Paradis, Catherine Postic, Dominique Rainteau, Eric Ogier-Denis, Maude Le Gall, Ulrich Meinzer, Emilie Viennois, Maite Casado-Bedmar, Alexis Mosca, Jean-Pierre Hugot
Journal: Gut Microbes (2024)

Metabolic syndrome (MetS) is a cluster of several human conditions including abdominal obesity, hypertension, dyslipidemia, and hyperglycemia, all of which are risk factors of type 2 diabetes, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease (MASLD). Dietary pattern is a well-recognized MetS risk factor, but additional changes related to the modern Western life-style may also contribute to MetS. Here we hypothesize that the disappearance of amoebas in the gut plays a role in the emergence of MetS in association with dietary changes. Four groups of C57B/6J mice fed with a high-fat diet (HFD) or a normal diet (ND) were colonized or not with
Liver transplantation for critically ill patients with acute on chronic liver failure: a prospective national programme of waitlist prioritisation
Authors: William Bernal, Rhiannon Taylor, Ian A Rowe, Abhishek Chauhan, Matthew J Armstrong, Michael E D Allison, Gwilym Webb, Tasneem Pirani, Joanna Moore, Laura Burke, Steven Masson, David Cressy, Brian J Hogan, Rachel Westbrook, Rajiv Jalan, Kenneth J Simpson, John Isaac, Douglas Thorburn
Journal: The Lancet Regional Health - Europe (2024)
Concerns about genetic risk testing for opioid use disorder
Authors: Alexander S Hatoum, Christal N Davis, Rachel L Kember, Mandy Johnstone, David W Oslin, Janneke R Zinkstok, Margit Burmeister, Arpana Agrawal, Henry R Kranzler, Howard J Edenberg, Joel Gelernter, Anna R Docherty, Todd Lencz
Journal: The Lancet Psychiatry (2024)
Privacy-friendly evaluation of patient data with secure multiparty computation in a European pilot study
Authors: Hendrik Ballhausen, Stefanie Corradini, Claus Belka, Dan Bogdanov, Luca Boldrini, Francesco Bono, Christian Goelz, Guillaume Landry, Giulia Panza, Katia Parodi, Riivo Talviste, Huong Elena Tran, Maria Antonietta Gambacorta, Sebastian Marschner
Journal: npj Digital Medicine (2024)

Abstract In multicentric studies, data sharing between institutions might negatively impact patient privacy or data security. An alternative is federated analysis by secure multiparty computation. This pilot study demonstrates an architecture and implementation addressing both technical challenges and legal difficulties in the particularly demanding setting of clinical research on cancer patients within the strict European regulation on patient privacy and data protection: 24 patients from LMU University Hospital in Munich, Germany, and 24 patients from Policlinico Universitario Fondazione Agostino Gemelli, Rome, Italy, were treated for adrenal gland metastasis with typically 40 Gy in 3 or 5 fractions of online-adaptive radiotherapy guided by real-time MR. High local control (21% complete remission, 27% partial remission, 40% stable disease) and low toxicity (73% reporting no toxicity) were observed. Median overall survival was 19 months. Federated analysis was found to improve clinical science through privacy-friendly evaluation of patient data in the European health data space.
Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF‐2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma
Authors: Yihao Zhu, Yajian Li, Xuwen Li, Yuan Yu, Lingpu Zhang, Hanchen Zhang, Can Chen, Dong Chen, Mingshuai Wang, Nianzeng Xing, Feiya Yang, Wahafu Wasilijiang, Xiongjun Ye
Journal: Advanced Healthcare Materials (2024)

Abstract Immune checkpoint blockers (ICBs) therapy stands as the first‐line treatment option for advanced renal cell carcinoma (RCC). However, its effectiveness is hindered by the immunosuppressive tumor microenvironment (TME). Sonodynamic therapy (SDT) generates tumor cell fragments that can prime the host's antitumor immunity. Nevertheless, the hypoxic microenvironment and upregulated autophagy following SDT often lead to cancer cell resistance. In response to these challenges, a hypoxia‐responsive polymer (Poly(4,4′‐azobisbenzenemethanol‐PMDA)‐mPEG 5k , P‐APm) encapsulating both a HIF‐2α inhibitor (belzutifan) and the ultrasonic sensitize (Chlorin e6, Ce6) is designed, to create the nanoparticle APm/Ce6/HIF. APm/Ce6/HIF combined with ultrasound (US) significantly suppresses tumor growth and activates antitumor immunity in vivo. Moreover, this treatment effectively transforms the immunosuppressive microenvironment from “immune‐cold” to “immune‐hot”, thereby enhancing the response to ICBs therapy. The findings indicate that APm/Ce6/HIF offers a synergistic approach combining targeted therapy with immunotherapy, providing new possibilities for treating RCC.
Single‐cell transcriptome atlas revealed bronchoalveolar immune features related to disease severity in pediatric <i>Mycoplasma pneumoniae</i> pneumonia
Authors: Xiantao Shen, Zhengjiang Jin, Xiaomin Chen, Zhenhui Wang, Lu Yi, Yangwei Ou, Lin Gong, Chengliang Zhu, Guogang Xu, Yi Wang
Journal: MedComm (2024)

The mechanisms underlying protective immunity in mild
Penfluridol inhibits melanoma growth and metastasis through enhancing von Hippel‒Lindau tumor suppressor‐mediated cancerous inhibitor of protein phosphatase 2A (CIP2A) degradation
Authors: Fuyan Xu, Jiao Li, Min Ai, Tingting Zhang, Yue Ming, Cong Li, Wenchen Pu, Yang Yang, Zhang Li, Yucheng Qi, Xiaomin Xu, Qingxiang Sun, Zhu Yuan, Yong Xia, Yong Peng
Journal: MedComm (2024)

Melanoma's high metastatic potential, especially to the brain, poses significant challenges to patient survival. The blood‒brain barrier (BBB) is a major obstacle to the effective treatment of melanoma brain metastases. We screened antipsychotic drugs capable of crossing the BBB and identified penfluridol (PF) as the most active candidate. PF reduced melanoma cell viability and induced apoptosis. In animal models, PF effectively inhibited melanoma growth and metastasis to the lung and brain. Using immunoprecipitation combined with high-resolution mass spectrometry, and other techniques such as drug affinity responsive target stability, we identified CIP2A as a direct binding protein of PF. CIP2A is highly expressed in melanoma and its metastases, and is linked to poor prognosis. PF can restore Protein Phosphatase 2A activity by promoting CIP2A degradation, thereby inhibiting several key oncogenic pathways, including AKT and c-Myc. Additionally, von Hippel‒Lindau (VHL) is the endogenous E3 ligase for CIP2A, and PF enhances the interaction between VHL and CIP2A, promoting the ubiquitin‒proteasome degradation of CIP2A, thereby inhibiting melanoma growth and metastasis. Overall, this study not only suggests PF's potential in treating melanoma and its brain metastases but also highlights CIP2A degradation as a therapeutic strategy for melanoma.
Targeting the <scp>IL</scp>‐5 pathway in eosinophilic asthma: A comparison of anti‐<scp>IL</scp>‐5 versus anti‐<scp>IL</scp>‐5 receptor agents
Authors: David J. Jackson, Michael E. Wechsler, Guy Brusselle, Roland Buhl
Journal: Allergy (2024)

Abstract Eosinophilic asthma is characterized by frequent exacerbations, poor symptom control and accelerated lung function decline. It is now recognized that the immune response underlying eosinophilic asthma involves a complex network of interconnected pathways from both the adaptive and innate immune systems. Within this response, interleukin‐5 (IL‐5) plays a central role in eosinophil differentiation, activation and survival and has emerged as a key target for therapies treating severe asthma. The monoclonal antibodies mepolizumab and reslizumab target the ligand IL‐5, preventing its interaction with eosinophils; in contrast, benralizumab binds to the IL‐5 receptor (IL‐5R), preventing IL‐5 from binding and leading to substantially greater eosinophil reduction by enhanced antibody‐dependent cell‐mediated cytotoxicity. Although no direct head‐to‐head clinical trials of asthma have been published to formally evaluate the clinical significance of these different therapeutic approaches, the potential benefits of partial versus complete eosinophil depletion continue to remain an important area of study and debate. Here, we review the existing real‐world and clinical study data of anti‐IL‐5/anti‐IL‐5R therapies in severe eosinophilic asthma.